Search

Your search keyword '"Gaul, Christoph"' showing total 157 results

Search Constraints

Start Over You searched for: Author "Gaul, Christoph" Remove constraint Author: "Gaul, Christoph"
157 results on '"Gaul, Christoph"'

Search Results

2. Supplementary Table S2 from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

3. Data from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

4. Supplementary Figures, Methods, and References from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

5. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

6. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

8. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements

9. 4-isopropyl-3-(methylthiomethyl)-5,5-diphenyloxazolidin-2-one: a chiral formyl anion equivalent for enantioselective preparations of 1,2-diols, 2-amino alcohols,2-hydroxy esters, and 4-hydroxy-2-alkenoates

10. Evolution of Novartis’ Small Molecule Screening Deck Design

11. Abstract 1770: A new DOT1L inhibitor with in vivo activity in mouse models of MLL-translocated leukemia

12. DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway

13. New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse

14. Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach

15. Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region

16. The migrastatin family: discovery of potent cell migration inhibitors by chemical synthesis

17. Discovery of potent cell migration inhibitors through total synthesis: lessons from structure-activity studies of (+)-migrastatin

18. Identification of Orally Available Naphthyridine Protein Kinase D Inhibitors

20. Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach

22. The total synthesis of (+)-migrastatin

24. 2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors

26. Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

27. Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

28. Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

29. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

30. Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition

31. Identification of Orally Available Naphthyridine Protein Kinase D Inhibitors

Catalog

Books, media, physical & digital resources